|
An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies Clinical research trials and An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies. An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies clinical trial. Participants typically obtain the most effective healthcare available for their An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies  An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies
An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies
For Condition: Multiple Myeloma
Status: Recruiting
Sponsor(s): University of Arkansas ,
Synopsis: The purpose of this study is to evaluate the use of thalidomide for the treatment of cancer. Patients with many types of cancers will be enrolled because the researchers will also study how the different cancers respond and what kind of side effects patients will experience.
Details: Angiogenesis is a normal, physiological process in the growing embryo, wound healing and ovulation. Progressive recruitments of blood vessels to the tumor site are thought to result in a self perpetuating loop helping to drive the growth of tumors. This new vasculature also allows competent tumor cells to find access to the vascular system and facilitate distant spread of tumor cells. Neovascularization is apparently an absolute prerequisite for physical expansion of solid tumors to grow beyond the volume of about 1-2 mm in diameter. Several molecular and cellular mechanisms have been identified by which tumor parenchyma may exert its angiogenic effect on host endothelial cells. There is also evidence that endothelial cells themselves, like other stromal cells, may act reciprocally to alter the behavior of adjacent tumor cells in a paracrine or cell contact mediated fashion. There is now known to be a diverse family of angiogenic growth factors, foremost among them being basic FGF and VEGF. Several angiogenic peptide genes have been sequenced and cloned. The degree of vascularization has acquired importance as an independent prognostic indicator in various types of solid tumors. More recently, it has been noted that increased angiogenesis may also be an important feature in hematologic malignancies, e.g. leukemia.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - All patients must have a confirmed malignancy which can be classified as locally advanced or distant metastatic disease and must have either 1) failed on standard therapy or 2) have disease for which in the opinion of the investigator, no adequate standard +therapy exists. - Patients must be 18 years of age or older. - Women of childbearing potential must have a negative pregnancy test and fertile women and men must use a medically acceptable means of birth control while on study and for 6 months thereafter. - Patients must sign an informed consent to participate in this study. - SWOG Performance status 0-3, unless related to cancer pain. - Before starting treatment, women of childbearing potential should have a negative pregnancy test performed within 24 hours prior to beginning therapy. - Pregnancy testing is not required for 1) women who have been post-menopausal for at least 2 years with no menses, 2) women who have had a hysterectomy. - Patients must have adequate hematologic function as demonstrated by total white blood count > 2000/mm3, adequate renal function as demonstrated by serum creatinine < 3.0 mg/dl, and adequate hepatic function as demonstrated by bilirubin < 1.5 mg/dl and transaminases < 4 x ULN. Exclusion Criteria - Patients must not be eligible for any UAMS participating clinical trial of higher priority.
Total Enrollment: 250
Location and Contact Information:
University of Arkansas for Medical Sciences/MIRT *Recruiting*
Little Rock, Arkansas, 72205
United States
Recruiting Mark Mosby 501-296-1503
Additional Information:
Study ID Numbers: UARK 98-023;
Study Start Date: September 1998
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00081757
Other Multiple Myeloma Studies:
1. Thalidomide for Multiple Myeloma
2. A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
3. Pyroxamide in Treating Patients With Advanced Cancer
4. Study of Combination PS-341 and Thalidomide in Multiple Myeloma
5. Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
Related Studies:
Other Multiple Myeloma Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies
|
|
|
|
|
|
|
|
